Volatile stock: In the newsletter
Volatile stock: In the newsletter
Day Trade watchlist:
SODA, LAKE, TKMR, BCRX, ADHD, EZPW, DECK, HA, OXGN, QLIK, TCS, GNW, EZPW, MBII, PANL, XCO, GNW
Pre Market Earning-
ISCA
After Hour Earning:
LNDC, MG, NG, YUM
Wednesday Premarket Earning
HAWK, COST, MON, RPM
Earning Preview with implied earning move:
In the newsletter
New IPO this week:
VKTX, HUBS, MOLG, NSIG, OMAM, USDP, VBTX, PlAY, DPLO
News that matter:
Hawaiian Airlines reports September 2014 traffic statistics; September RPMs increased 3.0% YoY, September ASMs up 0.3% YoY, Load Factor increased 2.2 points, passengers transported up 5.2% (HA)
OXiGENE announced that the data from the Phase 2 GOG186I study of fosbretabulin in combination with bevacizumab will be presented on November 9 at the International Gynecologic Cancer Society (OXGN)
Freeport-McMoRan announces agreement to sell its interests in Candelaria/Ojos for $1.8 bln in cash plus up to $0.2 bln in contingent consideration (FCX)
CalAmp beats by $0.02, reports revs in-line; guides Q3 EPS in-line, rev midpoint below consensus; guides FY15 EPS and rev in-line (CAMP)
Container Store reports EPS in-line, misses on revs; lowers FY15 guidance below consensus (TCS)
Team reports EPS in-line, misses on revs; reaffirms FY15 EPS guidance (TISI)
Asterias Biotherapeutics received approval to list its Series A common stock on the NYSE MKT under the ticker symbol AST -- to begin Oct 8 (ASTY)
Progenics Pharm receives $40 mln milestone following FDA approval of RELISTOR for OIC patients with chronic non-cancer pain (PGNX)
Regeneron Pharms: EYLEA (aflibercept) Injection receives FDA approval for macular edema following retinal vein occlusion (REGN)
Session | Time | Currency | Event | Impact | Actual | Forecast | Prev. | |||
---|---|---|---|---|---|---|---|---|---|---|
2:00 | EUR | German Industrial Production | med | -1.5 | 1.9 | |||||
2:00 | EUR | German Industrial Production | med | -0.5 | 2.5 | |||||
10:00 | USD | IBD consumer optimism | med | 45.2 | ||||||
15:00 | USD | Consumer Credit | med | 20 | 26.01 |
EXdividend:
In the newsletter
Top Gainer and loser:
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Upgrades and Downgrades:
In the newsletter
Sign up here for premium After hour and Premarket newsletter (2 day trial offer)
No comments:
Post a Comment